ELLA LEROY Corp — SEC Form D Filing

ELLA LEROY Corp filed an SEC Form D on August 11, 2026, reporting $50K raised in Pharmaceuticals.

Form D filing details

Filing
SEC Form D
Filing date
August 11, 2026
Amount reported
$50K
Round stage
Pre-Seed
Industry
Pharmaceuticals
Website
https://www.ellaleroy.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Patients suffer from severe pain and mental health conditions for which existing treatments are inadequate, representing unmet needs in the pharmaceutical field.

Solution

Ella LeRoy Corporation is developing innovative therapeutic solutions and effective therapies specifically designed to address severe pain and mental health conditions.

Why now

There is a continuous need for advanced therapeutic solutions in pain management and mental health, driven by ongoing research and increasing understanding of these complex conditions.

Verdict

This cleared because it presented a clear, high-value problem statement in a market with existing solutions, not because it demonstrated novel scientific breakthroughs. Investors were implicitly betting on the team's ability to navigate preclinical development and attract further institutional funding based on early-stage therapeutic promise. The limited upside stemmed from the early-stage nature of the science, offering little differentiation from other biopharma ventures targeting similar broad disease categories without specific platform or compound data.

Source: SEC EDGAR Form D filing